Anthony Philippakis
Venture Partner @ Google Ventures
Boston, United States
Anthony Philippakis is a Venture Partner at GV and a Chief Data Officer at Broad Institute. He was a Scientist at Broad Institute. Anthony attended Harvard Medical School, the University of Cambridge, and Yale University.
- Total investments:
- 26
- Last investment:
- Lead investor:
- 23%
Last updated:
For AI agents: llms.txt
Industries Anthony Philippakis invests in
Stages Anthony Philippakis invests in
Countries Anthony Philippakis invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 11 (42%)
- Health Care 10 (38%)
- Medical 6 (23%)
- Therapeutics 4 (15%)
- Life Science 3 (12%)
Stage
- Series A 9 (35%)
- Series B 6 (23%)
- Series C 4 (15%)
- Seed 2 (8%)
- Series D 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Arboretum LifeSciences develops precision medicine programs for common diseases. The company provides genetic testing programs for cardiovascular disease, cancer, and metabolic conditions through healthcare system partnerships. Its research participant platform supports electronic consent, survey collection, biospecimen coordination, research results, and matching to research opportunities. Its research analysis environment stores, curates, and analyzes research data. Arboretum LifeSciences also operates collaborative patient registries and supports clinical trial development based on genetic and health data. | $30M / Series A / Oct 06, 2026 | ||
| Iterative Health is a healthcare technology and services company that focuses on accelerating clinical research to improve patient outcomes through innovative approaches. The company transforms gastrointestinal (GI) care by utilizing AI-driven clinical trials and diagnostics, significantly enhancing access to vital treatments. | $77M / Series C / Apr 30, 2026 | ||
| Beacon Biosignals is a neurotechnology company focused on bringing precision neuroscience into clinical trials and treatments for brain- and sleep-related disorders. The company’s core offering includes an FDA-cleared wearable device (the Waveband headband) that captures high-fidelity EEG during sleep and wake states, combined with an AI-drivenanalytics platform that processes millions of hours of neural data to extract biomarkers of brain function. Its end-to-end solution supports pharmaceutical and biotech clients by providing tools for patient stratification, dose-response monitoring, and early-stage disease progression, enabling trials to be more precise and efficient. | $11M / Series B / Apr 06, 2026 | ||
| Prudentia Sciences is a platform enables AI-powered Asset Diligence and Valuation to De-Risk Investment in Drug Development. | $20M / Series A / Jan 07, 2026 | ||
| Beacon Biosignals is a neurotechnology company focused on bringing precision neuroscience into clinical trials and treatments for brain- and sleep-related disorders. The company’s core offering includes an FDA-cleared wearable device (the Waveband headband) that captures high-fidelity EEG during sleep and wake states, combined with an AI-drivenanalytics platform that processes millions of hours of neural data to extract biomarkers of brain function. Its end-to-end solution supports pharmaceutical and biotech clients by providing tools for patient stratification, dose-response monitoring, and early-stage disease progression, enabling trials to be more precise and efficient. | $86M / Series B / Nov 13, 2025 | ||
| Layer Health focuses on resolving the healthcare information problem by utilizing artificial intelligence to execute any clinical, administrative, or research work that involves chart review from unstructured data. | $29.5M / Series A / Mar 27, 2025 | ||
| Prudentia Sciences is a platform enables AI-powered Asset Diligence and Valuation to De-Risk Investment in Drug Development. | $7M / Seed / Jan 09, 2025 | ||
| Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses. | $101M / Series A / Nov 12, 2024 | ||
| Cardurion Pharmaceuticals is a Boston-based biotechnology company focused on developing novel therapeutics for the treatment of heart failure and other cardiovascular diseases. The company is advancing groundbreaking clinical programs targeting PDE9 and CaMKII inhibition, leveraging its expertise in cardiovascular signaling pathways to addressunmet patient needs. | $260M / Series B / Jul 16, 2024 | ||
| Moonwalk Biosciences is a genomic medicine startup that aims to provide a new class of precision epigenetic therapeutics. The company is working on the development of a profiling and engineering technology platform that, with the help of advanced artificial intelligence prediction, provides a comprehensive view of the epigenome in health anddisease, allowing healthcare providers to take a fresh look at how therapies are discovered and developed. | $57M / Series A / Jan 04, 2024 | ||
| See all 26 investments → | |||
Co-Investors
About Google Ventures
GV invests in sectors including life sciences, consumer, enterprise, crypto, climate, and frontier technology. With Alphabet as its sole limited partner, GV focuses on investments in North America and Europe. Its operating partners assist startups in design, equity, diversity & inclusion, talent, and engineering, and help them connect with Google for technology and expertise. Some investments include Uber, Nest, Slack, GitLab, and One Medical.
Google Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andy Wheeler
Partner
|
|||
Anika Gupta
Principal
|
|||
|
Anthony Philippakis
Venture Partner
|
|||
Ben Robbins
General Partner
|
|||
Bethany Tsui
Principal and Investor
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Anthony Philippakis invest in?
Anthony Philippakis invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 26 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Anthony Philippakis?
Public channels for Anthony Philippakis include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Anthony Philippakis last invest?
The most recent investment recorded for Anthony Philippakis closed in Oct 2026. Shizune tracks 26 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
